Tests a heart pump with heart medicines in heart failure and shock
Tests a heart pump device with heart medicines in adults with severe heart failure.
Key facts
- Who runs it
- Abiomed Inc.
- Where
- Charlotte, Dallas, Durham, Falls Church, Hackensack, Indianapolis, Minneapolis, Naples, Nashville, New Brunswick, New York, Philadelphia, Pittsburgh, Portland, Sacramento, Salt Lake City, San Francisco, St Louis, Tampa, Tulsa, Valhalla, and Winston-Salem, United StatesSee the 23 sites
- Trial code
- Registry title
- INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
- Status
- Recruiting
- People taking part
- 250 people, planned
- Started
- 2 Oct 2026
- Expected to end
- 1 Jun 2029
- Type of study
- Interventional
- Treatments tested
- Impella 5.5 SmartAssist
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a weak heart (LVEF ≤ 40%) who are in decompensated heart failure with cardiogenic shock and are not yet on enough heart failure medicines.
- Age
- 18 years or older and under 80 years
- Sex
- All sexes
- Disease stage
- Decompensated heart failure with LVEF ≤ 40% and at least two signs of cardiogenic shock: low blood pressure, poor blood flow to organs or lactate >2 mmol/L, cardiac index < 2.2 L/min/m2, or need for IABP or Impella CP support.
- Earlier treatment
- Before admission, on 2 or fewer of the 4 heart failure drug classes (BB, MRA, SGLT2i, RASi). Or, if on BB and RASi, at least one is below 50% of the maximal target dose.
Main reasons for not taking part
- Shock from non-cardiac causes, septic shock or mixed shock; cardiac arrest or SCAI Stage E shock before enrolment
- Acute coronary syndrome or ST-segment elevation; revascularization or cardiac surgery within 30 days
- On dialysis, kidney disease stage 4 and above, liver cirrhosis or other pre-existing liver disease, or lung disease needing oxygen
- Heart transplant history or plan, planned permanent VAD, or other mechanical support such as ECMO
- Any condition that prevents placing an Impella 5.5, or pregnancy
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Age ≥ 18 and < 80 years
- Subject or subject's legally authorized representative (LAR) has signed the Informed Consent Form
- LVEF ≤ 40%
- Subject is presenting with decompensated heart failure and meets at least two (2) of the following cardiogenic shock criteria:; Hypotension (sustained episode of systolic blood pressure ≤ 90 mmHg for at least 30 minutes or need for inotropic/vasoactive agents to maintain such blood pressure); Hypoperfusion (physical sign(s) of organ hypoperfusion or serum lactate >2 mmol/L); Cardiac index (CI) < 2.2 L/min/m2 determined to be secondary to cardiac dysfunction, in the absence of hypovolemia; Required support with an intra-aortic balloon pump (IABP) or Impella CP™
- Subject has inadequate heart failure GDMT based on the most recent outpatient prescription prior to index admission, defined as:; On 2 or less of the 4-Pillar HF Drug Classes (BB, MRA, SGLT2i, and RASi); If on BB and RASi, at least one of the two medications is < 50% of the maximal target dose
Who cannot take part
- Underlying unmodifiable conditions that limit initiation of GDMT prior to enrollment, including but not limited to:; Drug allergies or hypersensitivities* to HF GDMT medications, unless alternative can be identified; *Drug allergy/hypersensitivity is an immune-mediated reaction to a medication. Adverse reactions must be a result of immune or inflammatory cell stimulations by the mеԁiсаtion; Known bilateral renal artery stenosis; Type 1 diabetes; 2o or 3o AV block, unless pacemaker is in place; Angioedema, hereditary or idiopathic; Pregnancy, known or confirmed by a pregnancy test if of childbearing potential
- ST-segment elevation or acute coronary syndrome (ACS) prior to enrollment
- SCAI Stage E cardiogenic shock per study definition (Appendix C) prior to enrollment
- In cardiac arrest prior to enrollment
- Prolonged use (or use with complication) of Intra-aortic balloon pump (IABP) or Impella CP™ prior to enrollment, meeting at least one of the following:; IABP use >24 hours if placed at the enrolling site or >48 hours if transferred on IABP; Impella CP™ use >24 hours if placed at the enrolling site or >48 hours if transferred on Impella CP™; Experienced complication(s) from IABP including clinically significant vascular injury, limb ischemia, end organ damage, or bleeding requiring transfusion(s) per Investigator's discretion; Experienced complication(s) from Impella CP™ including clinically significant hemolysis, vascular injury, limb ischemia, end organ damage, or bleeding requiring transfusion(s) per Investigator's discretion
- On mechanical circulatory support other than IABP or Impella CP™ (i.e. ECMO, etc) or on mechanical ventilation for non-procedural reasons prior to enrollment
- Revascularization or cardiac surgery within 30-days prior to enrollment
- History of heart transplant or listed for heart transplant or planned for heart transplantation prior to enrollment
- Continuous outpatient inotropic support prior to the index hospitalization date
- Currently on dialysis, or has pre-existing end-stage chronic kidney disease (stage 4 and above), or has nephropathy of hereditary, infectious, or autoimmune origin
- History of stroke or intracranial hemorrhage ≤ 90 days prior to the index hospitalization date, or a history of cerebrovascular disease with significant (> 80%) uncorrected carotid stenosis, or any permanent neurological deficit with modified Rankin Scale (mRS) >2
- Intolerance to anticoagulant or antiplatelet therapies, or will refuse blood transfusions
- Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device
- Septic shock, shock from non-cardiac origins, or mixed shock
- Complex adult congenital heart disease
- Primary severe valvular disease
- Planned to pursue palliative care or hospice, or life expectancy of less than 1 year due to non-cardiac illness at the time of index hospitalization date
- Pre-existing functional liver disease including liver cirrhosis, alcoholic hepatitis, metabolic dysfunction associated steatohepatitis (MASH), or genetic liver disease
- Pre-existing pulmonary disease with oxygen dependency
- Any contraindication that precludes placing an Impella 5.5™, including but not limited to:; Aortic valve stenosis/calcification with orifice area ≤ 0.6cm2 or aortic insufficiency of any grade greater than mild on pre-procedure echocardiography; Presence of mechanical aortic valve or heart constrictive device; Mural thrombus in the left ventricle; Severe arterial disease precluding placement of Impella; Presence of atrial or ventricular septal defect; Left ventricular rupture; Cardiac tamponade; Combined cardiorespiratory failure
- Infection of the planned procedural access site or systemic active infection including sepsis and bacteremia
- Infiltrative/restrictive cardiomyopathy (sarcoidosis and amyloidosis), hypertrophic cardiomyopathy, constrictive pericarditis, pericardiac tamponade, or myocarditis requiring high-dose immunosuppression
- Predominant RV dysfunction per Investigator's discretion
- Planned to be implanted with a permanent VAD within 180-days of the index hospitalization date
- Subject has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with study procedures
- Subject belongs to a vulnerable population, such as prisoners, pregnant women, handicapped, mentally disabled persons, or economically or educationally disadvantaged persons per 21CFR56.111(a)(3) and 111(b)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Atrium Health- Sanger Heart and Vascular InstituteCharlotte, United StatesContact: Haley BonillaNot yet recruiting
- Medical City Heart Hospital DallasDallas, United StatesContact: Lauren HortonTaking people
- Duke UniversityDurham, United StatesContact: Elyse WilsonNot yet recruiting
- Inova Fairfax HospitalFalls Church, United StatesContact: Bhruga ShahNot yet recruiting
- Hackensack University Medical CenterHackensack, United StatesContact: Manuel CastilloNot yet recruiting
- Ascension St. VincentIndianapolis, United StatesContact: Jennifer BrownNot yet recruiting
- Abbott NorthwesternMinneapolis, United StatesContact: Juilanne FeolaTaking people
- NCH Rooney Heart InstituteNaples, United StatesContact: Kathy ByrdNot yet recruiting
- Centennial Medical CenterNashville, United StatesContact: Kristen KuhnNot yet recruiting
- Rutgers, Robert Wood Johnson Medical SchoolNew Brunswick, United StatesContact: Manisha Bajpai, MDTaking people
- New York Presbyterian - ColumbiaNew York, United StatesContact: Jessica IdumonyiNot yet recruiting
- University of Pennsylvania Health SystemPhiladelphia, United StatesContact: Alyson BrownNot yet recruiting
- Allegheny General HospitalPittsburgh, United StatesContact: Laurie MachenNot yet recruiting
- UPMC PresbyterianPittsburgh, United StatesContact: Traci Mc GahaNot yet recruiting
- Providence St. Vincent Medical CenterPortland, United StatesContact: Sarah JacksonNot yet recruiting
- Sutter Medical Center SacramentoSacramento, United StatesContact: Bonnie ChanNot yet recruiting
- University of UtahSalt Lake City, United StatesContact: Ashley ElmerNot yet recruiting
- California Pacific Medical CenterSan Francisco, United StatesContact: Bonnie ChanNot yet recruiting
- Barnes JewishSt Louis, United StatesContact: Jean FlanaganNot yet recruiting
- Tampa General HospitalTampa, United StatesContact: Courtney Nicholas, BS RN, CCRP, CVRN-BCTaking people
- Saint Francis Hospital - TulsaTulsa, United StatesContact: Jennifer NangleNot yet recruiting
- Westchester Medical CenterValhalla, United StatesContact: Rajkumari BhardwaNot yet recruiting
- Wake Forest Baptist Medical CenterWinston-Salem, United StatesContact: Karen Blinson Research CoordinatorNot yet recruiting
About the trial
What the trial wants to find out
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
The group in the trial
- Single arm studyOther group
This is a single arm study.
Treatment: Impella 5.5 SmartAssist
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Initiation and Titration of Guideline Directed Medical Therapy in Heart Failure Cardiogenic Shock With Impella 5.5 for Cardiac Recovery: INTeGRATE
- Plain-language title
- Tests a heart pump with heart medicines in heart failure and shockGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06965504, who can take part
- Record updated
- 12 November 2026